Abstract: The invention is a method for determining the concentration of an analyte in whole blood, wherein the analyte is a component which is contained in the blood, is different from a component occurring only in a red blood cell, and can generate hydrogen peroxide upon the reaction with an oxidase. Whole blood is utilized in the method. The method comprises the steps of hemolyzing the whole blood and detecting hydrogen peroxide generated by the reaction between the analyte and the oxidase. The measurement method can avoid the inhibition of color development by hemoglobin and the interference with the measurement by hemoglobin. Further it can be used for biological tests that are carried out in a household, an individual doctor's clinic or at the bedside of patients without the need for any blood cell separation procedure or the like, because the measurement utilizes whole blood.

Abstract: A protein comprising an amino acid sequence having at least one mutation selected from a Gly-4 to Ala mutation, a Glu-6 to His mutation, a Ser-14 to Thr mutation, an Ala-37 to Thr or Arg mutation, a Pro-50 to Gln mutation, a Glu-67 to Gly mutation, an Asp-80 to Tyr mutation, a Val-93 to Met mutation, an Arg-156 to Pro mutation, a Leu-164 to Met mutation, an Asn-202 to Asp mutation, a Thr-235 to Ala mutation, an Asn-348 to Tyr mutation, a Gly-362 to Arg mutation and a Val-473 to Ala mutation in the amino acid sequence depicted in SEQ II NO:4. (2) A thermostable protein which comprises an amino acid sequence derived from the amino acid sequence having at least one variation described in (1) and having 1,5-anhydroglucitol dehydrogenase activity. These proteins act specifically on 1,5-anhydroglucitol (1,5-AG), have thermal stability and exhibit excellent storage stability.

Abstract: A protein comprising an amino acid sequence having at least one mutation selected from a Gly-4 to Ala mutation, a Glu-6 to His mutation, a Ser-14 to Thr mutation, an Ala-37 to Thr or Arg mutation, a Pro-50 to Gln mutation, a Glu-67 to Gly mutation, an Asp-80 to Tyr mutation, a Val-93 to Met mutation, an Arg-156 to Pro mutation, a Leu-164 to Met mutation, an Asn-202 to Asp mutation, a Thr-235 to Ala mutation, an Asn-348 to Tyr mutation, a Gly-362 to Arg mutation and a Val-473 to Ala mutation in the amino acid sequence depicted in SEQ II NO:4. (2) A thermostable protein which comprises an amino acid sequence derived from the amino acid sequence having at least one variation described in (1) and having 1,5-anhydroglucitol dehydrogenase activity. These proteins act specifically on 1,5-anhydroglucitol (1,5-AG), have thermal stability and exhibit excellent storage stability.

Abstract: The invention is a method for determining the concentration of an analyte in whole blood, wherein the analyte is a component which is contained in the blood, is different from a component occurring only in a red blood cell, and can generate hydrogen peroxide upon the reaction with an oxidase. Whole blood is utilized in the method. The method comprises the steps of hemolyzing the whole blood and detecting hydrogen peroxide generated by the reaction between the analyte and the oxidase. The measurement method can avoid the inhibition of color development by hemoglobin and the interference with the measurement by hemoglobin. Further it can be used for biological tests that are carried out in a household, an individual doctor's clinic or at the bedside of patients without the need for any blood cell separation procedure or the like, because the measurement utilizes whole blood.

Abstract: A present invention relates to a method for quantitatively determining sugar-alcohols characterized by passing test samples containing sugar-alcohols, proteins, and saccharides through a column filled with basic anion-exchange resins which have a protein-removing ability and a saccharide-removing ability, and then quantitaing the sugar-alcohols in the effluent out of the column, a column filled with said resins and an aqueous solution of boric acid, and a kit. Sugar-alcohols such as 1,5-anhydroglucitol and the like have been calling attention as markers for diabetes mellitus recently.

Abstract: A present invention relates to a method for quantitatively determining sugar-alcohols characterized by passing test samples containing sugar-alcohols, proteins, and saccharides through a column filled with basic anion-exchange resins which have a protein-removing ability and a saccharide-removing ability, and then quantitaing the sugar-alcohols in the effluent out of the column, a column filled with said resins and an aqueous solution of boric acid, and a kit. Sugar-alcohols such as 1,5-anhydroglucitol and the like have been calling attention as markers for diabetes mellitus recently.

Abstract: This invention relates to a novel method for assaying 1,5-anhydroglucitol, which is expected to serve as a marker for diabetes, and a kit therefor. More particularly, it relates to:(1) a method for assaying 1,5-anhydroglucitol, which comprises selectively removing sugars from a specimen containing 1,5-anhydroglucitol; allowing pyranose oxidase or L-sorbose oxidase to act on 1,5-anhydroglucitol contained in the sample thus obtained in the presence of oxygen; and determining 1,5-anhydroglucitol from the amount of the hydrogen peroxide thus formed; and(2) a reagent kit for assaying 1,5-anhydroglucitol which comprises an agent for removing sugars, a reagent for detecting hydrogen peroxide and an enzyme for oxidizing 1,5-anhydroglucitol.

Abstract: The present invention relates to a method of quantitative assay for 1,5-anhydroglucitol which comprises oxidizing 1,5-anhydroglucitol in an aqueous solution of a specimen in the presence of an electron acceptor to produce a compound represented by formula (1) below or a hydrate thereof represented by formula (2) below and quantitatively determining 1,5-anhydroglucitol from a consumption amount of said electron acceptor in said aqueous solution of a specimen or from a production amount of the reduction product of said electron acceptor produced or from an amount of oxidized product of 1,5-AG represented by formula (1) or formula (2).

Abstract: Disclosed are an N-benzenesulfonyl derivative of cephamycin C represented by the following formula: ##STR1## which can easily be separated as a solid from an aqueous solution thereof, and a process for the preparation thereof.This derivative is valuable as an intermediate leading to a cephamycin type antibiotic substance.